全文获取类型
收费全文 | 45924篇 |
免费 | 2082篇 |
国内免费 | 180篇 |
专业分类
耳鼻咽喉 | 93篇 |
儿科学 | 993篇 |
妇产科学 | 598篇 |
基础医学 | 2978篇 |
口腔科学 | 224篇 |
临床医学 | 5434篇 |
内科学 | 21337篇 |
皮肤病学 | 165篇 |
神经病学 | 1452篇 |
特种医学 | 1835篇 |
外科学 | 9220篇 |
综合类 | 492篇 |
预防医学 | 1274篇 |
眼科学 | 183篇 |
药学 | 959篇 |
2篇 | |
中国医学 | 49篇 |
肿瘤学 | 898篇 |
出版年
2024年 | 21篇 |
2023年 | 2446篇 |
2022年 | 3766篇 |
2021年 | 4426篇 |
2020年 | 3713篇 |
2019年 | 2338篇 |
2018年 | 2023篇 |
2017年 | 1772篇 |
2016年 | 1629篇 |
2015年 | 1677篇 |
2014年 | 3996篇 |
2013年 | 2785篇 |
2012年 | 1909篇 |
2011年 | 1542篇 |
2010年 | 2184篇 |
2009年 | 2199篇 |
2008年 | 1196篇 |
2007年 | 1183篇 |
2006年 | 1040篇 |
2005年 | 830篇 |
2004年 | 627篇 |
2003年 | 631篇 |
2002年 | 581篇 |
2001年 | 517篇 |
2000年 | 374篇 |
1999年 | 428篇 |
1998年 | 316篇 |
1997年 | 259篇 |
1996年 | 252篇 |
1995年 | 253篇 |
1994年 | 193篇 |
1993年 | 131篇 |
1992年 | 114篇 |
1991年 | 93篇 |
1990年 | 105篇 |
1989年 | 113篇 |
1988年 | 94篇 |
1987年 | 24篇 |
1985年 | 35篇 |
1984年 | 48篇 |
1983年 | 44篇 |
1982年 | 33篇 |
1981年 | 29篇 |
1980年 | 34篇 |
1979年 | 24篇 |
1978年 | 24篇 |
1976年 | 21篇 |
1975年 | 24篇 |
1974年 | 23篇 |
1973年 | 17篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
52.
BackgroundThe collagen-based MANTA device (Teleflex, PA, USA) is used for closure of large-bore vascular access. There is a paucity of data on complications associated with its use in a real-life setting.MethodsWe queried the “Manufacturer and User Facility Device Experience” MAUDE database between February 2019 and December 2020 for reports on MANTA device.ResultsWe identified 250 reports in the MAUDE database from February 2019 through December 2020. The most common failure complication of MANTA is persistent bleeding (48.8%) and vessel occlusion or stenosis (29.6%). Most complications were managed successfully with an endovascular approach (48.4%), but a high number of patients required surgical intervention (40.4%). The most commonly reported failure mechanism was the failure of deployment (22%) followed by subcutaneous deployment (7.6%), intraluminal deployment (4.8%) amd detachment of collagen (2.8%). Access site infection was rare (1.2%). The 18 Fr. MANTA was associated with a lower risk of failure of deployment compared with the 14 Fr. device but was associated with a higher risk of vessel occlusion or stenosis (32.4% vs. 16.3%, p = 0.04) and thrombosis (11.6% vs 0%, p = 0.03).ConclusionsThe most common complication of the MANTA device reported to the MAUDE registry was persistent bleeding (48.8% of reports) followed by vessel occlusion (29.6%). These complications were managed successfully using an endovascular approach in 48.4% of the reports. 相似文献
53.
《Current problems in cardiology》2022,47(10):101297
Atrial fibrillation (AF) has a strong impact on the quality of life (QOL) of patients and anticoagulation has a lot to do with it. We evaluated the QOL of patients with nonvalvular AF who start treatment with apixaban in Latin America. QOL was analyzed through a questionnaire developed to evaluate anticoagulated patients, which was completed by them 3 months after starting treatment. We included 521 patients from Uruguay, Bolivia, Ecuador, Paraguay, and Peru. A high index of general treatment satisfaction (5.34 ± 0.46) and self-efficacy (5.11 ± 0.68) were observed; the distress index was low (1.77 ± 0.88), as was the perception of daily hassles (1.35 ± 0.49) and strain social network related to medication (1.21 ± 0.34). Patients with AF who started treatment with apixaban has good satisfaction and self-efficacy scores with low index of stress, few daily limitations and social disruptions. 相似文献
54.
Triposkiadis Filippos Xanthopoulos Andrew Skoularigis John Starling Randall C. 《Heart failure reviews》2022,27(6):1991-2003
Heart Failure Reviews - The nitric oxide (NO)–guanylate cyclase (GC)–cyclic guanosine monophosphate (cGMP) pathway plays an important role in cardiovascular, pulmonary and renal... 相似文献
55.
《Current problems in cardiology》2022,47(9):100902
Genistein, an isoflavone in soybean products has potential cardio-protective effects and is used also as an alternative for estrogen therapy in postmenopausal women. However, results in this regard are inconsistent and also, not all risk factors related to cardiovascular supportive effects have been meta-analyzed. We searched PubMed, Scopus, ISI Web of Science, and Google Scholar from inception up to October 2020. Random-effects meta-analysis was used for data synthesis. The search included studies with information on genistein supplementation and lipid profile [triglycerides (TG), total cholesterol (TC),low-density lipoprotein (LDL-C), and high-density lipoprotein HDL-C)], systolic and diastolic blood pressure (SBP & DBP), body mass index [BMI] and body weight. Pooled results of studies showed that genistein intake significantly reduced TC [95%CI: -0.49(-0.80, -0.18); P=0.002)], LDL-C [95%CI: -0.60(-1.10, -0.10); P=0.018)] and SBP [95%CI: -0.52(-0.90, -0.14); P=0.007)]. DBP, HLD-C, TG, BMI, and body weight showed no meaningful improvement. Subgroup analysis showed that LDL-C and SBP were reduced more effectively in postmenopausal women with metabolic syndrome. Genistein intake more than 6 months showed a greater effect on lowering cholesterol -0.76(-1.27, -0.24), SBP [-0.39(-0.70, -0.08)] and DBP -0.40(-0.81, -0.00) and increasing TG and LDL-C. This meta-analysis provides consistent evidence that genistein intake reduces the CVD risk factors of TC, LDL-C, and SBP significantly. 相似文献
56.
57.
58.
59.
60.